All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Excerpt
Striving towards a person-centred service through joint working across health and social care and cross-sector working (for example with commercial organisations) achieves the best possible outcomes for the person. This incorporates a patient's values and preferences and minimises harm, supporting effective medicines optimisation. This guideline reviews the evidence available to support health and social care practitioners, and health and social care organisations, in considering the systems and processes required to ensure safe and effective medicines optimisation.
In this guideline, the term ‘medicines’ covers all healthcare treatments, such as oral medicines, topical medicines, inhaled products, injections, wound care products, appliances and vaccines. The guideline will assume that prescribers will use a medicine's summary of product characteristics to inform decisions made with individual patients.
Contents
- Guideline development group members
- Acknowledgements
- 1. Introduction
- 2. Development of a NICE clinical guideline
- 3. Methods
- 4. Guideline summary
- 5. Systems for identifying, reporting and learning from medicines-related patient safety incidents
- 6. Medicines-related communication systems when patients move from one care setting to another
- 7. Medicines reconciliation
- 8. Medication review
- 9. Self-management plans
- 10. Patient decision aids used in consultations involving medicines
- 11. Clinical decision support
- Medicines-related models of organisational and cross-sector working
- 13. Reference list
- 14. Glossary
- Appendices
NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales.
This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summary of product characteristics of any drugs.
Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
- NLM CatalogRelated NLM Catalog Entries
- Medicines OptimisationMedicines Optimisation
Your browsing activity is empty.
Activity recording is turned off.
See more...